Atrial Fibrillation (AF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Atrial Fibrillation (AF) Market Outlook

Thelansis’s “Atrial Fibrillation (AF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrial Fibrillation (AF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Atrial Fibrillation (AF) Overview

Atrial fibrillation (AF) is the most typical sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke. AF causes an estimated 15% of all strokes, and it accounts for one-third of strokes in individuals aged 65 years or older. AF is a complex disease with only a partly elucidated pathophysiology; it is the subject of extensive medical research, believing that a complete understanding of AF will yield novel drug therapies with improved effectiveness and safety profiles over current drugs. In keeping with other forms of cardiac arrhythmia, both a triggering factor and a substrate are thought to be required for AF induction; early-stage research has identified several novel targets that have the potential to prevent abnormal impulse formation (the trigger) and help reverse long-term structural and electrical remodeling. Guidelines prepared by the American Heart Association (AHA)/The American College of Cardiology (ACC)/European Society of Cardiology (ESC) classify AF into four major categories. Atrial fibrillation (AF) is classified based on its duration and reversibility into sinus rhythm. The last three categories apply to recurrent AF episodes. The first-detected episode of AF can be symptomatic or self-limiting, and the diagnosing physician may be uncertain about the episode's duration and previous episodes.

• Atrial fibrillation (AF) prevalence increased from 0.1% among adults younger than 55 years to 8.5% in 80 years or older persons. Approximately 2.12 MN to 2.4 MN US adults are currently diagnosed with AF.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: